FDA spurns CytoDyn’s HIV drug because of missing info

CytoDyn rejected by the FDA

CytoDyn rejected by the FDA.

The FDA rejected CytoDyn’s application for its lead program, an antibody to treat HIV in combination with antiretroviral therapy, because it’s missing some information, the company announced on Monday—two months after it revealed it had previously sent the wrong datasets to the agency.

The agency said in a refusal-to-file letter that the Biologics License Application (BLA) for leronlimab “does not contain certain information needed to complete a substantive review,” according to a CytoDyn statement. The Vancouver, Washington-based company did not specify what that information was but expressed confidence that it could produce what the agency wanted.

CytoDyn doesn’t need to carry out more clinical trials to fulfill the FDA’s request, the company said, adding that it would further analyze data from trials it has already finished.

The company’s stock dropped 9% Monday morning on the news before rebounding, but it closed at $3.70, down more than 20% from Friday’s closing price.

CytoDyn says it’s developing leronlimab for various diseases, including breast cancer, graft versus host disease, nonalcoholic steatohepatitis (NASH) and—you guessed it—COVID-19. It announced in April that the BLA for the antibody as a treatment for HIV infection was complete, but backtracked in May, saying it actually had been incomplete until then. The reason? It had included “mock datasets” instead of “clinical datasets.”

In the Monday statement, CytoDyn CEO Nader Pourhassan, Ph.D., pivoted from HIV to COVID-19: “We are 100% committed and confident we can provide the necessary information to the FDA as soon as possible. No additional trials will be required and all the information the FDA has requested is obtainable. While we await upcoming results in our two major COVID-19 Phase 2 and Phase 3 trials, we are confident July will be very important month for our shareholders.”

The company is testing the antibody against placebo in a phase 2b/3 study in 390 patients after having provided the drug to 54 patients with severe COVID-19 infection under an Emergency Investigational New Drug application from the FDA. It also has a phase 2 study underway in patients with mild to moderate disease.

Early Data Show Moderna’s Coronavirus Vaccine Is 94.5% Effective

Early Data Show Moderna’s Coronavirus Vaccine Is 94.5% Effective Moderna Inc said it will request authorization for emergency use in Read more

Pfizer's coronavirus vaccine sparks optimism

Pfizer's coronavirus vaccine sparks optimism. The European Commission announced this Wednesday an agreement reached with the pharmaceutical firms Pfizer and Read more

Breathonix develops non-invasive breath tests for disease detection

Breathonix develops non-invasive breath tests for disease detection. Singapore’s Breathonix has said a clinical trial of its COVID-19 breathalyzer test Read more

45 vaccine candidates in human trials

45 vaccine candidates in human trials. Governments, companies, health systems and citizens scrutinize with great interest to know when a Read more

Spain will be one of the European economies with a fall in the largest economy

Spain will be one of the European economies with a fall in the largest economy. It was an open secret. Read more

Airbus starts negotiating its industrial plan next week

Airbus starts negotiating its industrial plan next week. Airbus (PA: AIR) recorded 2,686 million euros in losses between January and Read more

We all know that there is enough oil in the world, the problem is in the demand and how it will recover after this crisis

We all know that there is enough oil in the world, the problem is in the demand and how it Read more

Grifols starts the trial to test its immunoglobulin in patients with Covid-19

Grifols starts the trial to test its immunoglobulin in patients with Covid-19. Grifols has announced the start of the clinical Read more

The European Union approves extraordinary funds of 750 billion for recovery after the pandemic

The European Union approves extraordinary funds of 750 billion for recovery after the pandemic.   With a «We did it! Read more

Moderna claims its COVID-19 vaccine produces a "robust" immune response

Moderna claims its COVID-19 vaccine produces a "robust" immune response. Scientists around the world will continue to search for a Read more

Leave a Reply